Dual therapy (atazanavir/ritonavir¿+¿lamivudine) versus standard triple therapy [atazanavir/ritonavir¿+¿two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Academic Article2017
Overview
Additional Document Info
Otro
Ver todos
Overview
authors
Perez-Molina JA
Rubio R Rivero A Pasquau J Suárez-Lozano I Riera M Estébanez M Palacios R Sanz-Moreno J Troy
Moreno S
GeSIDA 7011 Study Group (Gutierrez F Masiá M among others)